Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02382549
Title A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Craig L Slingluff, Jr
Indications

melanoma

Therapies

6MHP vaccine + Dabrafenib + Trametinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.